公开(公告)号：US11920196B2

公开(公告)日：2024-03-05

申请号：US17337163

申请日：2021-06-02

Applicant: University Health Network

Inventor： Mohit Kapoor ,  Rajiv Gandhi ,  Shabana Amanda Ali

IPC: C12Q1/6876

CPC classification number: C12Q1/6876 ,  C12Q2600/178

Abstract: A method comprising obtaining a substantially cell-free sample of blood plasma or blood serum from a subject with osteoarthritis; and detecting a presence of or measuring a level of novel_miRNA_1 (gucuggcucaggguuggg) (SEQ ID NO: 1), novel_miRNA_2 (ucccuguucgggcgccacu) (SEQ ID NO: 2), novel_miRNA_3 (uguuuagcauccuguagccugc) (SEQ ID NO: 3), and novel_miRNA_4 (uaguggguuaucagaacu) (SEQ ID NO: 4). Also provided are methods where additional miRNAs are detected including novel miRNA 5 (SEQ ID NO: 5), novel miRNA 6 (SEQ ID NO: 6), novel miRNA 7 (SEQ ID NO: 7), novel miRNA 8 (SEQ ID NO: 8), novel miRNA 9 (SEQ ID NO: 9), novel miRNA 10 (SEQ ID NO: 10), novel miRNA 11 (SEQ ID NO: 11), novel miRNA 12 (SEQ ID NO: 12), novel miRNA 13 (SEQ ID NO: 13), hsa-miR-335-3p, hsa-miR-199a-5p, hsa-miR-671-3p, hsa-miR-1260b, hsa-miR-191-3p, hsa-miR-335-5p and/or hsa-miR-543.

公开(公告)号：US11908568B2

公开(公告)日：2024-02-20

申请号：US17077413

申请日：2020-10-22

Applicant: CANON MEDICAL SYSTEMS CORPORATION ,  University Health Network

Inventor： Ting Xia ,  Zhou Yu ,  Patrik Rogalla ,  Bernice Hoppel

IPC: G06T7/00 ,  G16H30/20 ,  G06N3/04 ,  G16H50/30 ,  G16H50/20

CPC classification number: G16H30/20 ,  G06N3/04 ,  G06T7/0014 ,  G16H50/20 ,  G16H50/30 ,  G06T2207/10028 ,  G06T2207/10081 ,  G06T2207/30168

Abstract: The present disclosure relates to a method for patient-specific optimization of imaging protocols. According to an embodiment, the present disclosure relates to a method for generating a patient-specific imaging protocol, comprising acquiring scout scan data, the scout scan data including scout scan information and scout scan parameters, generating a simulated image based on the acquired scout scan data, deriving a simulated dose map from the generated simulated image, determining image quality of the generated simulated image by applying machine learning to the generated simulated image, the neural network being trained to generate at least one probabilistic quality representation corresponding to at least one region of the generated simulated image, evaluating the determined image quality relative to a image quality threshold and the derived simulated dose map relative to a dosage threshold, optimizing. based on the evaluating, scan acquisition parameters and image reconstruction parameters, and generating, optimal imaging protocol parameters, wherein the optimal imaging protocol parameters maximize image quality while minimizing radiation exposure.

公开(公告)号：US11857317B2

公开(公告)日：2024-01-02

申请号：US17961480

申请日：2022-10-06

Applicant: The Trustees of Dartmouth College

Inventor： Pablo Valdes ,  Frederic Leblond ,  Keith D. Paulsen ,  Brian Campbell Wilson ,  David W. Roberts ,  Michael Jermyn

IPC: A61B5/1455 ,  A61B5/1459 ,  A61B1/04 ,  A61B5/145 ,  A61B5/00 ,  A61B5/1495 ,  A61B1/06 ,  A61B5/055 ,  G01J3/28 ,  A61B1/05 ,  G01J3/12 ,  G01J3/02 ,  A61B1/00 ,  A61B1/07 ,  A61B1/313

CPC classification number: A61B5/14556 ,  A61B1/00009 ,  A61B1/000094 ,  A61B1/00165 ,  A61B1/00193 ,  A61B1/00194 ,  A61B1/042 ,  A61B1/043 ,  A61B1/05 ,  A61B1/0646 ,  A61B1/0669 ,  A61B1/0684 ,  A61B1/07 ,  A61B5/0071 ,  A61B5/0077 ,  A61B5/055 ,  A61B5/1459 ,  A61B5/1495 ,  A61B5/14546 ,  A61B5/14553 ,  A61B5/7264 ,  G01J3/0229 ,  G01J3/1256 ,  G01J3/2823 ,  A61B1/3132 ,  G01J2003/1269 ,  G01J2003/2826

Abstract: An imaging system, such as a surgical microscope, laparoscope, or endoscope or integrated with these devices, includes an illuminator providing patterned white light and/or fluorescent stimulus light. The system receives and images light hyperspectrally, in embodiments using a hyperspectral imaging array, and/or using narrowband tunable filters for passing filtered received light to an imager. Embodiments may construct a 3-D surface model from stereo images, and will estimate optical properties of the target using images taken in patterned light or using other approximations obtained from white light exposures. Hyperspectral images taken under stimulus light are displayed as fluorescent images, and corrected for optical properties of tissue to provide quantitative maps of fluorophore concentration. Spectral information from hyperspectral images is processed to provide depth of fluorophore below the tissue surface. Quantitative images of fluorescence at depth are also prepared. The images are displayed to a surgeon for use in surgery.

公开(公告)号：US20230330152A1

公开(公告)日：2023-10-19

申请号：US18336410

申请日：2023-06-16

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Gordon KELLER ,  April M. CRAFT

IPC: A61K35/32 ,  C12N5/077 ,  G01N33/50

CPC classification number: A61K35/32 ,  C12N5/0655 ,  G01N33/5044 ,  C12N2501/115 ,  C12N2501/155 ,  C12N2501/16 ,  C12N2501/415 ,  C12N2501/999 ,  C12N2503/02 ,  C12N2506/02 ,  C12N2506/03

Abstract: A method for generating chondrocytes and/or cartilage, optionally articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue and/or hypertrophic chondrocyte like cells and/or cartilage like tissue, the method comprising:

a. culturing a primitive streak-like mesoderm population, optionally a CD56+, PDGFRalpha+ KDR- primitive streak-like mesoderm population, with a paraxial mesoderm specifying cocktail comprising:

i. a FGF agonist;
ii. a BMP inhibitor; optionally Noggin, LDN-193189, Dorsomorphin; and
iii. optionally one or more of a TGFbeta inhibitor, optionally SB431524; and a Wnt inhibitor, optionally DKK1, IWP2, or XAV939;

to specify a paraxial mesoderm population expressing cell surface CD73, CD105 and/or PDGFR-beta;
b. generating a chondrocyte precursor population comprising:

i. culturing the paraxial mesoderm population expressing CD73, CD105 and/or PDGFR-beta at a high cell density optionally in serum free or serum containing media;
ii. culturing the high cell density CD73+, CD105+ and/or PDGFRbeta+ paraxial mesoderm population with a TGFbeta3 agonist in serum free media to produce a high cell density Sox9+, collagen 2+ chondrocyte precursor population; and


c. either

i. culturing the high cell density Sox9+, collagen 2+ chondrocyte precursor population with the TGFbeta3 agonist for an extended period of time to produce an articular like non-hypertrophic chondrocyte cells and/or cartilage like tissue; or
ii. culturing the high cell density Sox9+ collagen2+ chondrocyte precursor population with a BMP4 agonist for an extended period of time to produce a hypertrophic chondrocyte like cells and/or cartilage like tissue.

公开(公告)号：US20230302096A1

公开(公告)日：2023-09-28

申请号：US18047129

申请日：2022-10-17

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Philippe P. MONNIER ,  Nardos G. TASSEW

IPC: A61K38/44 ,  A61K31/137 ,  C07K16/28 ,  A61K31/724 ,  A61K31/365 ,  A61K31/7048 ,  A61K38/48 ,  C07K14/435 ,  C07K14/705 ,  G01N33/53 ,  A61K31/495 ,  A61K38/17 ,  G01N33/50

CPC classification number: A61K38/443 ,  A61K31/137 ,  C07K16/28 ,  C12Y101/03006 ,  A61K31/724 ,  A61K31/365 ,  A61K31/7048 ,  A61K38/482 ,  C07K14/435 ,  C07K14/705 ,  G01N33/53 ,  A61K31/495 ,  A61K38/177 ,  G01N33/5058 ,  A61K2039/505

Abstract: Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.

公开(公告)号：US11766437B2

公开(公告)日：2023-09-26

申请号：US16635320

申请日：2018-08-01

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Mark Robert Bray ,  Jacqueline M. Mason ,  Tak W. Mak ,  Graham Fletcher

IPC: A61K31/519 ,  A61P35/00 ,  A61K39/395

CPC classification number: A61K31/519 ,  A61K39/3955 ,  A61P35/00

Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula: (I) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

公开(公告)号：US11751817B2

公开(公告)日：2023-09-12

申请号：US15701091

申请日：2017-09-11

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： T. Douglas Bradley ,  Geoffrey Roy Fernie ,  Hisham Alshaer ,  Ahmad Ziad Akl

IPC: A61B5/00 ,  A61B7/00

CPC classification number: A61B5/7282 ,  A61B5/7475 ,  A61B7/003 ,  A61B5/4818 ,  A61B5/6803

Abstract: Disclosed herein are breathing disorder identification, characterization and diagnosis methods, devices and systems. In general the disclosed methods, devices and systems may rely on the characterization of breath sound amplitudes, periodic breath sounds and/or aperiodic breath sounds to characterize a breathing disorder as obstructive (e.g. obstructive sleep apnea—OSA) or non-obstructive (e.g. central sleep apnea—CSA).

公开(公告)号：US20230263400A1

公开(公告)日：2023-08-24

申请号：US17456001

申请日：2020-05-27

Applicant: THE COVERNING COUNCIL OF THE UNIVERSITY TORONTO ,  UNIVERSITY HEALTH NETWORK

Inventor： Daniyal LIAQAT ,  Mohamed ABDALLA ,  Eyal DE LARA ,  Frank RUDZICZ ,  Andrea GERSHON ,  Robert Wu

IPC: A61B5/02 ,  A61B5/00

CPC classification number: A61B5/02 ,  A61B5/7275

Abstract: Systems and methods for filtering time-varying data for filtering and extracting a predicted physiological signal. A method including: segmenting the time-varying data into temporal windows; using a trained filter machine learning model, predicting an error for each prediction of the physiological signal for each window of time-varying data, the filter machine learning model trained using physiological signal predictions based on training time-varying data and known values of the physiological signal for the training time-varying data; discarding each window of time-varying data when the predicted error for such window is greater than a threshold; and where the window of time-varying data is not discarded, outputting at least one of the window of time-varying data and the predicted error for each prediction of the physiological signal.

公开(公告)号：US20230257769A1

公开(公告)日：2023-08-17

申请号：US18098328

申请日：2023-01-18

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Valerie WALLACE ,  Arturo ORTIN-MARTINEZ

IPC: C12N15/85 ,  A61K35/30 ,  A61P27/02

CPC classification number: C12N15/8509 ,  A61K35/30 ,  A61P27/02

Abstract: There is described herein a photoreceptor cell comprising a neurotoxin transgene, methods for making the same, and use of the same for vision treatment.

公开(公告)号：US20230245315A1

公开(公告)日：2023-08-03

申请号：US18148861

申请日：2022-12-30

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Ralph DACOSTA

IPC: G06T7/00 ,  A61B5/00 ,  G01N21/64

CPC classification number: G06T7/0016 ,  A61B5/0071 ,  A61B5/0077 ,  A61B5/445 ,  G01N21/6486 ,  G06T2207/10016 ,  G06T2207/10024 ,  G06T2207/10048 ,  G06T2207/10064 ,  G06T2207/30088 ,  G06T2207/30096

Abstract: An adaptor for configuring a mobile communication device for tissue imaging is disclosed. The adaptor includes a housing configured to be removably coupled to a mobile communication device, at least one excitation light source for fluorescent imaging, a white light source for white light imaging, and a power source for powering the adaptor. The excitation light source is configured to emit light in one of ultraviolet, visible, near-infrared, and infrared ranges.